C4 Therapeutics Inc. (NASDAQ: CCCC) dropped 50.57% after announcing Cohort A from the ongoing Phase 1/2 clinical study of CFT7455, a proprietary degrader that targets IKZF1/3 for non-Hodgkin’s lymphomas and multiple myeloma. The company has learned a lot from only five melanoma patients in the study’s first cohort. Now, C4 Therapeutics Knows that its product candidate requires a different dosing schedule relative to the same products in the same category before it. Also, they have demonstrated CFT455’s potency designed to be the next generation IKZF1/3 degrader. IKZF1/3is a protein that is known to trigger multiple myeloma.
Interestingly the company has evidence supporting the hypothesis that CFT7455 can be administered as monotherapy without the challenging steroid known as dexamethasone that has been used in this degrader therapy in multiple myeloma treatment.
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) was down 37.81% after announcing a halt of the enrolment of three clinical trials evaluating its investigational drug BCX9930. According to a news release, patient participation in the Redeem-1, Redeem-2, and Renew clinical studies have been halted while BioCryst explores high serum creatinine levels found in certain patients. A high amount of creatinine can signal serious renal disease.
It is not possible to know how significant the potential problems have impacted the trials. Patients who have already enrolled in clinical studies will keep receiving BCX9930 for the time being, according to BioCryst.
BioCryst will likely resume enrolment after finalizing its investigation. However, the situation is likely to worsen should the three studies be put on clinical hold because of elevated creatinine levels. It is important to note that the company doesn’t depend solely on BCX9930 since its hereditary angioedema drug Orladeyo is currently on the market. The company anticipates the drug to generate sales of around $250 million this year and hit highs of $1 billion.
Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) dropped 30.02% after announcing initial safety and efficacy data from the ongoing Phase 1b study of ZN-c3 in combination with chemo in patients with refractory or platinum-resistant ovarian cancer. The company reviewed the data as a poster at the American Association of Cancer Research Annual Meeting happening in Louisiana between April 8 and 13, 2022.
The company’s CEO, Dr. Anthony Sun, stated that the initial combination clinical activity confirmed from the ongoing study supports ZN-C3’s potential best-in-class safety and efficacy profile and demonstrates its synergistic combinability with other chemotherapies. ZN-c3, which utilizes continuous dosing in people with advanced disease, showed an ORR of 30.2% in all cohorts and surprisingly better tolerability in the Wee1 inhibitor class.
Preliminary data from the first phase monotherapy USC expansion cohort that received ZN-c3 >300 mg QD were also released. The company plans to release updated data from the USC expansion group of the Phase 1 monotherapy study at the mini-symposium on April 11, 2022.
Before you plow your money into them… think about this.
You can generate income on a weekly basis simply by trading BLUE CHIP, HIGH VOLUME stocks that are ALREADY on the move.
We call these ‘red zone’ trades… because they’re already on the five yard line… and they’re about to score.